$BOLT
Bolt Biotherapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022016460 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $2.112M $1.393M $813.0K
YoY Change 164.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.485M $5.532M $6.304M
YoY Change 11.01% 36.46% 46.6%
% of Gross Profit
Research & Development $18.97M $18.92M $18.39M
YoY Change -1.88% -3.99% 30.14%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K $357.0K
YoY Change 31.58% 100.0% 31.25%
% of Gross Profit
Operating Expenses $24.46M $24.45M $24.69M
YoY Change 0.74% 2.91% 33.99%
Operating Profit -$22.35M -$23.06M -$23.88M
YoY Change -5.02% -2.95% 29.58%
Interest Expense $587.0K $395.0K $198.0K
YoY Change 348.09% 124.43% 230.0%
% of Operating Profit
Other Income/Expense, Net $587.0K $395.0K $198.0K
YoY Change 124.43% -103.28%
Pretax Income -$21.76M -$22.66M -$23.68M
YoY Change -6.99% -3.91% -3.16%
Income Tax
% Of Pretax Income
Net Earnings -$21.76M -$22.66M -$23.68M
YoY Change -6.99% -3.91% -3.17%
Net Earnings / Revenue -1030.26% -1626.99% -2912.42%
Basic Earnings Per Share -$0.58 -$0.61 -$0.64
Diluted Earnings Per Share -$0.58 -$607.7K -$637.7K
COMMON SHARES
Basic Shares Outstanding 37.64M 37.52M 37.43M
Diluted Shares Outstanding 37.45M 37.29M 37.13M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $171.1M $176.3M $190.9M
YoY Change -19.62% -28.02% -28.42%
Cash & Equivalents $10.62M $22.62M $44.02M
Short-Term Investments $160.5M $153.7M $146.9M
Other Short-Term Assets $3.696M $4.927M $5.187M
YoY Change -61.48% 55.77% 15.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $174.8M $181.3M $196.1M
YoY Change -21.42% -26.95% -27.7%
LONG-TERM ASSETS
Property, Plant & Equipment $6.905M $6.525M $6.637M
YoY Change 22.62% 43.38% 69.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $38.43M $47.28M $54.31M
YoY Change -50.5% -28.29% 50.04%
Other Assets $1.000M $997.0K $916.0K
YoY Change -60.86% -59.0% 340.38%
Total Long-Term Assets $70.68M $78.98M $86.71M
YoY Change -36.36% -20.17% 62.29%
TOTAL ASSETS
Total Short-Term Assets $174.8M $181.3M $196.1M
Total Long-Term Assets $70.68M $78.98M $86.71M
Total Assets $245.5M $260.2M $282.8M
YoY Change -26.4% -25.02% -12.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.828M $3.362M $4.446M
YoY Change -25.74% 108.3% 53.95%
Accrued Expenses $17.18M $11.75M $11.41M
YoY Change 28.83% -11.68% 50.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.17M $18.62M $19.31M
YoY Change 2.02% -3.26% 60.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $200.0K $204.0K
YoY Change -99.43% -99.37% -36.45%
Total Long-Term Liabilities $200.0K $200.0K $204.0K
YoY Change -99.43% -99.37% -36.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.17M $18.62M $19.31M
Total Long-Term Liabilities $200.0K $200.0K $204.0K
Total Liabilities $57.06M $52.27M $54.40M
YoY Change -2.69% 2.13% 154.33%
SHAREHOLDERS EQUITY
Retained Earnings -$275.1M -$253.3M -$230.7M
YoY Change 61.94% 73.57%
Common Stock $465.2M $463.1M $460.5M
YoY Change 2.38% 5.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $188.4M $208.0M $228.4M
YoY Change
Total Liabilities & Shareholders Equity $245.5M $260.2M $282.8M
YoY Change -26.4% -25.02% -12.89%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$21.76M -$22.66M -$23.68M
YoY Change -6.99% -3.91% -3.17%
Depreciation, Depletion And Amortization $400.0K $400.0K $357.0K
YoY Change 31.58% 100.0% 31.25%
Cash From Operating Activities -$13.45M -$20.79M -$24.31M
YoY Change -28.17% 421.63% 46.83%
INVESTING ACTIVITIES
Capital Expenditures -$735.0K -$429.0K $605.0K
YoY Change -27.59% -38.8% 943.1%
Acquisitions
YoY Change
Other Investing Activities $2.185M -$439.0K $41.45M
YoY Change -114.47% -99.04% -121.76%
Cash From Investing Activities $1.450M -$868.0K $40.85M
YoY Change -109.0% -98.14% -121.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.0K
YoY Change -17.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 252.0K 107.0K
YoY Change -100.0% -98.12% -99.96%
NET CHANGE
Cash From Operating Activities -13.45M -20.79M -24.31M
Cash From Investing Activities 1.450M -868.0K 40.85M
Cash From Financing Activities 0.000 252.0K 107.0K
Net Change In Cash -12.00M -21.40M 16.64M
YoY Change -65.37% -42.43% -81.5%
FREE CASH FLOW
Cash From Operating Activities -$13.45M -$20.79M -$24.31M
Capital Expenditures -$735.0K -$429.0K $605.0K
Free Cash Flow -$12.72M -$20.36M -$24.92M
YoY Change -28.21% 519.91% 49.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
632000
us-gaap Depreciation
Depreciation
500000
dei Entity Central Index Key
EntityCentralIndexKey
0001641281
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
997000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39988
dei Entity Registrant Name
EntityRegistrantName
Bolt Biotherapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2804636
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Chesapeake
dei Entity Address Address Line2
EntityAddressAddressLine2
Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
665-9295
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Trading Symbol
TradingSymbol
BOLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37641459
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22618000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27383000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
153717000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
158836000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4927000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2941000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
181262000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
189160000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6525000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6158000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22607000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24445000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
47281000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
85348000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
463103000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1042000
CY2022Q2 us-gaap Assets
Assets
260237000
CY2021Q4 us-gaap Assets
Assets
307718000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3362000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3574000
CY2022Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9607000
CY2021Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12384000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3508000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2869000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2145000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2501000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18622000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21328000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20749000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21854000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12698000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14207000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
210000
CY2022Q2 us-gaap Liabilities
Liabilities
52269000
CY2021Q4 us-gaap Liabilities
Liabilities
57599000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37641459
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37641459
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37399694
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37399694
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457430000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1803000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-321000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253332000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206990000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250119000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
260237000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29088267
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
228394000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
us-gaap Net Income Loss
NetIncomeLoss
-48039000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1482000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23071000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307718000
CY2022Q2 us-gaap Revenues
Revenues
1393000
us-gaap Revenues
Revenues
2206000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18920000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19707000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37305000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33834000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5532000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4054000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11836000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8353000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24452000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
23761000
us-gaap Operating Expenses
OperatingExpenses
49141000
us-gaap Operating Expenses
OperatingExpenses
42187000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23059000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23761000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46935000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42187000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
395000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
176000
us-gaap Investment Income Net
InvestmentIncomeNet
593000
us-gaap Investment Income Net
InvestmentIncomeNet
232000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
395000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
176000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
593000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5852000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23544000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47824000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48062000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37293557
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36595112
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37211174
CY2022Q2 bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
2000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2391000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
303248000
CY2021Q2 bolt Issuance Of Common Stock Related To Stock Purchase Agreement
IssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
148444000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11406000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
CY2021Q2 bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
88000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2023000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250119000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
4000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5310000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1482000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-104947000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
188506000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241959000
bolt Issuance Of Common Stock Related To Stock Purchase Agreement
IssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
152000
bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
98000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4132000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Net Income Loss
NetIncomeLoss
-48039000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
295896000
us-gaap Profit Loss
ProfitLoss
-46342000
us-gaap Profit Loss
ProfitLoss
-48039000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
765000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
528000
us-gaap Share Based Compensation
ShareBasedCompensation
5310000
us-gaap Share Based Compensation
ShareBasedCompensation
4132000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-693000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1011000
bolt Change In Fair Value Of Convertible Preferred Stock Purchase Rights Liabilities
ChangeInFairValueOfConvertiblePreferredStockPurchaseRightsLiabilities
6084000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1838000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1174000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1941000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3087000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4110000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1461000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-278000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-870000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11363000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20545000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39977000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9538000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1034000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
761000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8403000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
107433000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
247768000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3013000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2245000
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6525000
CY2022Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-237123000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
51902000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
244316000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
359000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
572000
bolt Proceeds From Issuance Of Common Stock Related To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockRelatedToStockPurchaseAgreement
13638000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
359000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310428000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4765000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52760000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7107000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24183000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59867000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22618000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58302000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24183000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59867000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
4000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
98000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
98000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
226000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14884000
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
202801000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6158000
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, stock-based compensation and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. As of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, most of the Company’s funds were invested with a registered investment manager and custodied at one financial institution, with working capital kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions where the funds are held.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
800000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1600000
CY2021Q2 us-gaap Depreciation
Depreciation
200000
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q2 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5674000
CY2021Q4 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6300000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3027000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1803000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
200998000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
244505000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
333000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
244184000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2258000
CY2022Q2 bolt Lessee Operating Sublease Income Receivable Remainder Of Fiscal Year
LesseeOperatingSubleaseIncomeReceivableRemainderOfFiscalYear
397000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4612000
CY2022Q2 bolt Lessee Operating Sublease Income Due Next Twelve Months
LesseeOperatingSubleaseIncomeDueNextTwelveMonths
403000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4886000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
906000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1198000
CY2022Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9607000
CY2021Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12384000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.111
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.107
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1041000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
902000
us-gaap Operating Lease Cost
OperatingLeaseCost
2175000
us-gaap Operating Lease Cost
OperatingLeaseCost
1669000
us-gaap Operating Lease Payments
OperatingLeasePayments
2289000
us-gaap Operating Lease Payments
OperatingLeasePayments
666000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4772000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4227000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3371000
CY2022Q2 bolt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16338000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35578000
CY2022Q2 bolt Lessee Operating Sublease Income
LesseeOperatingSubleaseIncome
800000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12684000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
22894000
us-gaap Sublease Income
SubleaseIncome
800000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2391000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2023000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5310000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4132000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23585000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
us-gaap Net Income Loss
NetIncomeLoss
-48039000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37517136
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36617390
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37475641
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29104022
CY2022Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
223579
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
22278
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
264466
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
33553
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
17798
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37293557
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36595112
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37211174
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29088267
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7929023
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5102618

Files In Submission

Name View Source Status
0000950170-22-016460-index-headers.html Edgar Link pending
0000950170-22-016460-index.html Edgar Link pending
0000950170-22-016460.txt Edgar Link pending
0000950170-22-016460-xbrl.zip Edgar Link pending
bolt-20220630.htm Edgar Link pending
bolt-20220630.xsd Edgar Link pending
bolt-20220630_cal.xml Edgar Link unprocessable
bolt-20220630_def.xml Edgar Link unprocessable
bolt-20220630_htm.xml Edgar Link completed
bolt-ex10_1.htm Edgar Link pending
bolt-ex31_1.htm Edgar Link pending
bolt-ex31_2.htm Edgar Link pending
bolt-ex32_1.htm Edgar Link pending
bolt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img5893999_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
bolt-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bolt-20220630_lab.xml Edgar Link unprocessable